• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax?) overcomes pregnancy-associated immune sup

tetano

Editor, Senior Moderator
Vaccine. 2014 Jun 20. pii: S0264-410X(14)00858-5. doi: 10.1016/j.vaccine.2014.06.057. [Epub ahead of print]
A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax?) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection.
Honda-Okubo Y1, Kolpe A1, Li L1, Petrovsky N2.
Author information
Abstract

Pregnant women and neonates represent high-risk groups for influenza infection, and in general have suppressed responses to standard influenza vaccines due to pregnancy-associated immune suppression and immune system immaturity, respectively. We therefore wished to test whether addition of Advax?, a polysaccharide adjuvant based on delta inulin, to an inactivated influenza vaccine (A/H1N1/PR8) administered during pregnancy would safely enhance vaccine immunogenicity and thereby provide improved protection of pregnant mothers and also potentially their newborns. Pregnant mice received a single intramuscular injection of β-propiolactone inactivated H1N1 antigen alone or with Advax adjuvant. Pregnant dams receiving Advax adjuvanted vaccine exhibited significantly increased serum and breast milk anti-influenza IgG titers. This translated into higher serum anti-influenza IgG titers in the pups of these dams. Complete protection was seen in pups of dams that received Advax-adjuvanted vaccine whereas no survival was seen in pups of control mothers or mothers immunized with unadjuvanted vaccine. Cross-fostering studies confirmed that enhanced protection of pups of dams that received Advax-adjuvanted vaccine was mediated by enhanced transfer of maternal IgG to the pups via breast-feeding. The delta inulin adjuvant was not associated with any reproductive or developmental adverse effects. This study shows that Advax adjuvant was safe when administered with influenza vaccine during pregnancy and provided protection of pups not seen with administration of unadjuvanted vaccine, via enhanced breast milk transfer of anti-influenza antibodies.

Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:

Adjuvant; Breast feeding; Immunity; Influenza; Neonate; Pregnancy; Vaccine

PMID:
24958701
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24958701
 
Back
Top Bottom